Update on Adult Dermatomyositis
DOI:
https://doi.org/10.37287/ijghr.v8i3.1387Keywords:
dermatomyositis, diagnosis, risk factor, treatmentAbstract
Dermatomyositis is a systemic autoimmune disorder that is an inflammatory disease of the skin, muscles, and blood vessels with characteristic skin eruptions accompanied by proximal limb muscle weakness or atrophy. This condition can affect children and adults. The pathognomonic lesions are the heliotrope sign, Gottron's papule, and Gottron's sign Malignancy can occur in 10%- 20%, with nasopharyngeal cancer being the most common. Etiology and pathogenesis are autoimmune; other triggers include drugs, infection, sun exposure, and malignancy. The latest diagnosis criteria by EULAR/ACR 2017 and Sontheimer et al. can be used as a reference for diagnosis. Comprehensive management of dermatomyositis aims to decrease symptoms, increase quality of life, and early detection of malignancy. Topical therapy options for dermatomyositis are topical calcineurin inhibitors and corticosteroids. In addition, systemic therapy consists of steroid- sparing agents, antimalarials, and corticosteroids. The current treatment of dermatomyositis is the administration of intravenous Immunoglobulin (IVIG) and rituximab.
References
Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N. Dermatomyositis: Current concepts. Clin Dermatol. 2018 Jul - Aug. 36 (4):450-458.
Bottai M, Tjärnlund A, Santoni G, et al. EULAR/ ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open 2017;3:e000507. doi:10.1136/ rmdopen-2017- 000507.
Briani C, Doria A, Sarzi-Puttini P, et al. Update on idiopathic inflammatory myopathies.
Autoimmunity. 2006;39:161-170. doi: 10.1080/08916930600622132.
Cassius Charles, Buanec L H. Biomarkers in Adult Dermatomyositis: Tools to Help the Diagnosis and Predict the Clinical Outcome. Januari 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350546/.
Chung MP, Richardson C, Kirakossian D, Orandi AB, Saketkoo LA, Rider LG, et al. Calcinosis biomarkers in adult and juvenile dermatomyositis Autoimmun Rev. 2020(19):1-9. doi: 10.1016/j.autrev.2020.102533.
Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21:339–53. doi: 10.1007/s40257-020-00502-6
Dermatomyositis: An Update on Diagnosis and Treatment - PubMed (nih.gov).
Concha JSS, Tarazi M, Kushner CJ, Gaffney RG, Werth VP. The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria. Br J Dermatol. 2019;180:1001– 8. doi: 10.1111/bjd.17536.
DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2020 Feb. 82 (2):267-281.
Griger Z, Nagy-Vincze M, Dankó K. Pharmacological management of dermatomyositis. Expert Rev. Clin Pharmacol. 2017;10:1109–18. doi: 10.1080/17512433.2017.135391.
Goldsmith, LA, Kats, SI, Gillchrest, BA, Paller, AS, Leffell, DJ, Wolff, K 2012, Fitzpatrick’s Dermatology in General Medicine, 8th ed. E-book: The McGraw-Hill companies, New York.Taylor C, Badreshia S, Callender V. Treatments For Skin of Color. 2011;
H. 1926 – 1942.
Gouda W, Albasri A, Alsaqabi F. Dermatomyositis Following BNT162b2 mRNA Covid-19 Vaccination. 2022. https://doi.org/10.3346/jkms.2022.37.e32.
Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/ dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121: 91–9. doi: 10.1016/j.rmed.2016.10.019.
James WD, Elston DM, Treat JR, Rosenbach MA, Neuhaus IM. Connective Tissue Diseases. In: Andrews’s Diseases of The Skin: Clinical Dermatology. Edisi ke-13. Philadelphia: WB Saunders; 2020.p.157-66.
Lewis M, Fiorentino D. Dermatomyositis. Dalam: Kang et al. Fitzpatrick’s Dermatology. Edisi
ke-9. New York City: McGraw Hill Education; 2019.h.1061–1081.
Leclair V, Lundberg IE. New myositis classification criteria—what we have learned since Bohan and Peter. Curr Rheumatol Rep 2018;20:1-8. doi: 10.1007/ s11926-018- 0726-4.
Marzecka M, Niemczyk A, Rudnicka L. Autoantibody Markers of Increased Risk of Malignancy in Patient with Dermatomyositis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464248/ (Accessed 11 Februari 2022).
Menaldi S, Bramono K, Inriatmi W. Ilmu Penyakit Kulit dan Kelamin. 7th ed. Jakarta: Fakultas Kedokteran Universitas Indonesia. 2019. Chapter 6, Dermatomiositis: H. 309 - 271. Okogbaa J, Batiste L. Dermatomyositis: an acute flare and current treatments. Clin
Med Insights: Case Rep. 2019:1-7. doi: 10.1177/1179547619855370.
Pawitri A, Miranda E. Dermatomiositis: Diagnosis dan Tata Laksana. eJKI.2022;10(1). Qudsiya Zainab, Waseem Muhammad. Dermatomyositis 2022. Available from :
https://www.ncbi.nlm.nih.gov/books/NBK558917/. [Accessed 08 Agustus 2022]. Rayavarapu, S., Coley, W., Kinder, T.B., dan Nagaraju, K. Idiopathic Inflammatory
Myopathies: Pathogenic Mechanisms of Muscle Weakness. Skeletal Muscle Journal 3: 13, 2013.
Sena P, Gianatti A, Gambini D. Dermatomyositis: clinicopathological correlations. Giornale Italiano di Dermatologia e Venereologia. 2018; 153(2):256-64.
Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018(20):1-
7. doi: 10.1007/s11926-018-0733-5.
Zhang L, Wu G, Gao D, Liu G, Pan L, Ni L, et al. Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLoS One. 2016(5):1-12. doi: 10.1371/journal.pone.0155381.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
